934-20-3

Basic information

• Product Name: (2E)-2-(hydroxymethylidene)cycloheptanone
• CAS NO: 934-20-3
• Molecular Formula: C₈H₁₂O₂
• Molecular Weight: 140.1797
• Mol File: 934-20-3.mol

Chemical Properties

• Boiling Point: 257.2°C at 760 mmHg
• Flash Point: 106.5°C
• Density: 1.178g/cm³
• Vapor Pressure: 0.00219mmHg at 25°C
• Refractive Index: 1.591
• CAS DataBase Reference: (2E)-2-(hydroxymethylidene)cycloheptanone(CAS DataBase Reference)
• NIST Chemistry Reference: (2E)-2-(hydroxymethylidene)cycloheptanone(934-20-3)
• EPA Substance Registry System: (2E)-2-(hydroxymethylidene)cycloheptanone(934-20-3)

Safety Data

• Hazardous Substances Data: 934-20-3(Hazardous Substances Data)

Usage

Uses

Used in Medicine:
(2E)-2-(hydroxymethylidene)cycloheptanone is used as a pharmaceutical agent for its potential applications in medicine, including its antimicrobial and antiviral properties, which make it a promising candidate for further research and development in the medical field.
Used in Polymer Synthesis:
In the polymer industry, (2E)-2-(hydroxymethylidene)cycloheptanone is used as a chelating agent and inhibitor of metal-catalyzed oxidation, which aids in the synthesis of polymers by preventing unwanted side reactions and improving the overall quality of the final product.
Used in Food Preservation:
As an antioxidant, (2E)-2-(hydroxymethylidene)cycloheptanone is utilized in food preservation to extend the shelf life of products by inhibiting oxidation processes that can lead to spoilage and degradation of food quality.
Used in Antimicrobial Applications:
(2E)-2-(hydroxymethylidene)cycloheptanone is used as an antimicrobial agent due to its ability to inhibit the growth of microorganisms, making it a valuable component in products that require protection against microbial contamination.

Upstream product

• 109-94-4 formic acid ethyl ester 
• 502-42-1 cycloheptanone 
• 64-17-5 ethanol 
• 7182-08-3 4-(1-cyclohepten-1-yl)morpholine 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 14745-97-2 2-(2-amino-anilinomethylene)-cycloheptanone 
• 142335-73-7 4-(Benzyl-methyl-amino)-3-phenyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyran-2-one 
• 107647-52-9 1-formyl-2-benzylcyclohept-1-ene 
• 107647-51-8 1-Benzyl-2-[1-trimethylsilanyloxy-meth-(E)-ylidene]-cycloheptanol 
• 871112-21-9 ethyl 4-[2-(2-oxocycloheptylidene)hydrazino]benzoate 
• 375359-31-2 ethyl 6-oxo-5,6,7,8,9,10-hexahydrocyclohepta[b]indole-2-carboxylate 
• 7257-25-2 7,8,9,10-tetrahydrocyclohepta[b]indol-6(5H)-one 
• 1135-67-7 1-phenyl-cyclohexanecarboxylic acid 
• 1056563-09-7 C₂₅H₂₉N₃O₄S 
• 1056564-16-9 C₂₄H₂₆ClN₃O₂ 
• 106180-60-3 (Z)-3-(3,4-pentano-2-furyl)-2-phenylacrylnitrile 
• 106180-61-4 (E)-3-(3,4-pentano-2-furyl)-2-phenylacrylnitrile 
• 106180-46-5 (Z)-3-<2-(2-Phenylethynyl)-1-cycloheptenyl>-oxirane-2-carbonitrile 
• 106180-46-5 (E)-3-<2-(2-Phenylethynyl)-1-cycloheptenyl>-oxirane-2-carbonitrile 

Relevant articles and documents

Discovery of a subnanomolar and selective spirocyclic agonist of the glucocorticoid receptor

Pure diastereomeric spirocyclic analogs of fluorocortivazol were conveniently prepared by a short and efficient synthetic sequence recently developed in our laboratory. The structures and conformations of several key products were confirmed by single crystal X-ray diffraction analysis. Conformational assignments were also supported by DFT calculations. Biological evaluation led to the identification of a highly potent hGR agonist with excellent anti-inflammatory effects in the subnanomolar range. All tested compounds from this series were also selective versus the progesterone receptor.

Cascade cyclization: An easy access to highly unsaturated polycyclic ring systems through a tandem stille/[4 + 2] reaction under mild conditions

(matrix presented) The synthesis of several polycyclic compounds 1a-c, 2, and 3 has been performed through a tandem Stille/[4 + 2] cascade reaction from cyclic bis(enoltrifluomethanesulfonate) 4a-c, 5, and 6, respectively. The reaction proceeds very effic

SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF

The present invention relates to compounds according to Formula (I-1) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

Stereospecific Construction of Contiguous Quaternary All-Carbon Centers by Oxidative Ring Contraction

Oxidative ring contraction of cyclic α-formyl ketones was facilitated by the action of H2O2under operationally simple and environmentally benign reaction conditions. The process was highly regioselective and enables stereospecific construction of contiguous quaternary all-carbon centers from stereodefined all-substituted all-cyclic ketones. The asymmetric syntheses of (+)-cuparene and (+)-tochuinyl acetate were also successively achieved by taking advantage of this novel protocol.

Synthesis and Oxidative Cleavage of Oxazinocarbazoles: Atropselective Access to Medium-Sized Rings

Polycyclic systems can be converted into medium-sized-ring-containing compounds through the controlled oxidative cleavage of internal double bonds. This approach is particularly accessible in systems that contain a suitably substituted indole ring. Here, a robust approach to the synthesis of the understudied oxazinocarbazole system is reported. After regioselective incorporation of a carbonyl functional group, m-chloroperoxybenzoic acid (MCPBA) is used to cleave the indole 2,3-double bond that this system contains. This results in a competition between two processes, oxidative cleavage of the double bond and a pinacol-type rearrangement, both of which occur with very high diastereoselectivity. The balance between the two processes is studied as a function of the substrate structure. Extensive use of X-ray crystallographic analysis of the products enables detailed mechanistic conclusions to be drawn.

A novel necroptosis inhibitor - Necrostatin-21 and its SAR study

An initial structure-activity relationship study of the novel necroptosis inhibitor Nec-21 was described. Any changes of the tetracyclic scaffold were detrimental for the activity. Introduction of a substituent to 7 or 8 position (e.g., cyano or methoxy group, respectively), would increase the activity. The 7 and 8-position disubstituted compound 17b was 35-fold as potent as the lead, while EC50 reached 14 nM.

A back-to-front fragment-based drug design search strategy targeting the DFG-out pocket of protein tyrosine kinases

We present a straightforward process for the discovery of novel back pocket-binding fragment molecules against protein tyrosine kinases. The approach begins by screening against the nonphosphorylated target kinase with subsequent counterscreening of hits against the phosphorylated enzyme. Back pocket-binding fragments are inactive against the phosphorylated kinase. Fragment molecules are of insufficient size to span both regions of the ATP binding pocket; thus, the outcome is binary (back pocket-binding or hinge-binding). Next, fragments with the appropriate binding profile are assayed in combination with a known hinge-binding fragment and subsequently with a known back pocket-binding fragment. Confirmation of back pocket-binding by Yonetani-Theorell plot analysis progresses candidate fragments to crystallization trials. The method is exemplified by a fragment screening campaign against vascular endothelial growth factor receptor 2, and a novel back pocket-binding fragment is presented.

Synthesis of bicyclic salicylates by [3+3] cyclization of 1,3-bis(silyl enol ethers) with cyclic 3-(silyloxy)alk-2-en-1-ones

Bicyclic salicylates were prepared by [3+3] cyclization of 1,3-bis(silyl enol ethers) with cyclic 3-(silyloxy)alk-2-en-1-ones.

INDOLE DERIVATIVE AND USE FOR TREATMENT OF CANCER

The present invention relates to a compound represented by the formula (I’) wherein A is a benzene ring optionally having substituents, R1, R2a and R3 are each a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, R1 and R2a may form a ring via X, when R1 and R2a form a ring via X, R1 and R2a are each a bond or a divalent C1-5 acyclic hydrocarbon group optionally having substituents, and X is a bond, an oxygen atom, an optionally oxidized sulfur atom or an imino group optionally having a substituent, provided that R1, R2a and X are not bonds at the same time, or a salt thereof, and an agent for inhibiting kinase (phosphorylation enzyme), which contains this compound or a prodrug thereof. The compound of the present invention has an inhibitory activity against kinase such as a vascular endothelial growth factor receptor (VEGFR) and the like, and is useful as an agent for the prophylaxis or threatment of cancer and the like.